KC-3254

CHOK1-CD38 Cell Line

×
34260
Home » CHOK1-CD38 Cell Line

Background of CHOK1-CD38 Cell Line

CD38 (Cluster of Differentiation 38) , also known as ADPRC1 (ADP-ribosyl cyclase 1) or T10, is a type II transmembrane glycoprotein with bifunctional ectoenzyme activity. It catalyzes the synthesis of cyclic ADP-ribose (cADPR) from NAD⁺, a second messenger involved in calcium mobilization, and also functions as a NAD glycohydrolase. CD38 is widely expressed on hematopoietic cells, including B cells, T cells, NK cells, and plasma cells, and is also found in various non-hematopoietic tissues. It plays a critical role in immune regulation, cell adhesion, and signal transduction. CD38 is highly overexpressed in multiple myeloma (MM) and various B-cell malignancies, making it an established therapeutic target. The monoclonal antibody daratumumab (anti-CD38) has been FDA-approved for multiple myeloma, and other CD38-targeting agents, including isatuximab and antibody-drug conjugates, are in clinical use or development for hematological malignancies.

Specifications

Catalog NumberKC-3254
Cell Line NameCHOK1-CD38 Cell Line
NCBI/UniProt Accession NumberNM_001775.4
Clone Number3#
Host Cell LineCHOK1 Cell Line
DescriptionStable CHOK1 cell line expressing exogenous human CD38 gene.
QuantityOne vial of frozen cells (≥2×106 cells)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20% FBS+10% DMSO
Propagation MediumRPMI1640+10%FBS+10µg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial-like
SubcultureSplit saturated culture 1:4-1:8 every 2-3 days
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 30 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

The CHOK1-CD38 cell line was generated using a lentiviral vector expressing the human CD38 sequence.

Characterization

Figure 1: Characterization of human CD38 overexpression in the CHOK1-CD38 stable clone using FACS.

Figure 2: Characterization of endogenous CD38 expression in CHOK1 cells using FACS.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO2 incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4-1:8 every 2-3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the cell pellet in chilled freezing medium, ensuring a minimum cell density of 3×106 cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

1. Piedra-Quintero, Zayda L et al. “CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity.” Frontiers in immunology vol. 11 597959. 30 Nov. 2020, doi:10.3389/fimmu.2020.597959
2. Gozzetti, Alessandro et al. “Anti CD38 monoclonal antibodies for multiple myeloma treatment.” Human vaccines & immunotherapeutics vol. 18,5 (2022): 2052658. doi:10.1080/21645515.2022.2052658
3. Bocuzzi, Valentina et al. “CD38 as theranostic target in oncology.” Journal of translational medicine vol. 22,1 998. 5 Nov. 2024, doi:10.1186/s12967-024-05768-6
4. van de Donk, Niels W C J et al. “CD38 antibodies in multiple myeloma: back to the future.” Blood vol. 131,1 (2018): 13-29. doi:10.1182/blood-2017-06-740944
5. Li, Yanli et al. “CD38 as an immunomodulator in cancer.” Future oncology (London, England) vol. 16,34 (2020): 2853-2861. doi:10.2217/fon-2020-0401

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.